Barclays PLC Aadi Bioscience, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Barclays PLC holds 11,356 shares of AADI stock, worth $20,440. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,356
Previous 22,261
48.99%
Holding current value
$20,440
Previous $45,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding AADI
# of Institutions
64Shares Held
13.7MCall Options Held
4.9KPut Options Held
700-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.13 Million0.08% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.33 Million3.54% of portfolio
-
Satter Management Co., L.P.1.63MShares$2.94 Million4.26% of portfolio
-
Black Rock Inc. New York, NY1.04MShares$1.87 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA857KShares$1.54 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $37.8M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...